Abstract
Significant progress in the development of potent and selective histamine H-1-receptor agonists has been achieved since 1990. Optimisation of the class of 2-phenylhistamines has furnished 2-[3(trifluoromethyl)phenyl]histamine and its N-alpha-methyl derivative. The discovery of histaprodifen (2-[2-(3,3-diphenylpropyl)-1H-imidazol-4-yl]ethanamine) and the novel lead compound suprahistaprodifen ...
Abstract
Significant progress in the development of potent and selective histamine H-1-receptor agonists has been achieved since 1990. Optimisation of the class of 2-phenylhistamines has furnished 2-[3(trifluoromethyl)phenyl]histamine and its N-alpha-methyl derivative. The discovery of histaprodifen (2-[2-(3,3-diphenylpropyl)-1H-imidazol-4-yl]ethanamine) and the novel lead compound suprahistaprodifen (N-alpha-2-[(1H-imidazol-4-yl)ethyl]histaprodifen) represents additional milestones in the H-1-receptor agonist field.
Altmetric